HUTCHMED (China) Limited (LON:HCM – Get Rating) crossed below its 200-day moving average during trading on Thursday . The stock has a 200-day moving average of GBX 317.13 ($3.89) and traded as low as GBX 195.80 ($2.40). HUTCHMED shares last traded at GBX 200 ($2.45), with a volume of 56,547 shares trading hands.
Separately, Citigroup restated a “buy” rating and set a GBX 220 ($2.70) price target on shares of HUTCHMED in a research note on Thursday, June 23rd.
The stock has a market cap of £1.91 billion and a P/E ratio of -10.98. The company has a debt-to-equity ratio of 3.75, a current ratio of 3.89 and a quick ratio of 3.73. The business’s 50 day simple moving average is GBX 184.34 and its 200 day simple moving average is GBX 315.07.
HUTCHMED (China) Limited discovers, develops, and commercializes targeted therapeutics and immunotherapies for cancer and immunological diseases in HongKong and internationally. It operates in Oncology/Immunology and Other Ventures segments. The company develops Savolitinib, an inhibitor for non-small cell lung cancer (NSCLC), papillary and renal cell carcinoma, colorectal cancer (CRC), and gastric cancer (GC); and Fruquintinib, an inhibitor for CRC, breast cancer, GC, endometrial cancer (EMC), NSCLC, hepatocellular carcinoma, and gastrointestinal and solid tumors.
Further Reading
- Schnitzer Steel Witnesses A Strong Quarter On The Back Of Strong Domestic Demand
- MarketBeat: Week in Review 6/27 – 7/1
- Accolade Moves Higher But Growth Is Slowing
- ZIM Integrated Shipping Services (ZIM): Don’t Miss This Dividend
- RH Gives Good Reason To Get Defensive
Receive News & Ratings for HUTCHMED Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for HUTCHMED and related companies with MarketBeat.com's FREE daily email newsletter.